Latest Content

The frontline combination of encorafenib, cetuximab, and FOLFIRI yielded significant improvement vs SOC in BRAF V600E-mutated metastatic colorectal cancer.

Margarita Huober, AGNP, AOCNP, explains that understanding a patient on an individual level leads to more informed care decisions in RCC.

Data link physical activity with reduced cancer-related fatigue in patients with colorectal cancer.

Transportation is a key accessibility issue for patients with HR-positive metastatic breast cancer receiving CDK4/6 inhibitors at community clinics.

Findings from a real-world, head-to-head comparison show greater colorectal cancer risk reduction and safety with the use of a GLP-1RA vs aspirin.

Median PFS over 1 year and median OS over 2 years have been observed for the first time in a phase 3 trial for gastroesophageal adenocarcinoma.

ECOG performance status of 1 was linked with worse patient-reported outcomes in patients with gastric or gastroesophageal junction adenocarcinoma.

Zolbetuximab plus mFOLFOX6 and nivolumab led to meaningful gains in patients with unresectable gastric/gastroesophageal junction adenocarcinoma.

Destiny-Breast09 PROs demonstrated higher quality of life and fewer gastrointestinal symptoms in patients with HER2-positive advanced breast cancer.

Nursing ethics expert Katherine Brown-Saltzman, MA, RN, shares insights on how to manage difficult ethical issues when treating patients with cancer.

Expert advice for administering and monitoring liso-cel in patients with follicular lymphoma.

The microbiota-based therapy MaaT013 showed promising efficacy and manageable safety in those with acute GVHD with gastrointestinal involvement.

Look back at the top 5 updates for oncology nurses and advanced practices providers published in 2025.